Evidence map›Paper›PMID 26094816›Full record

ArticleImmunology2015

Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells.

Marta Siernicka, Magdalena Winiarska, Malgorzata Bajor, Malgorzata Firczuk, Angelika Muchowicz, Malgorzata Bobrowicz, Cyril Fauriat, Jakub Golab, Daniel Olive, Radoslaw Zagozdzon

Open access · bronzeAbstract read
In one paragraph

Article in Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Marta SiernickaDepartment of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
Magdalena WiniarskaDepartment of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
Malgorzata BajorDepartment of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
Malgorzata FirczukDepartment of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
Angelika MuchowiczDepartment of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
Malgorzata BobrowiczDepartment of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
Cyril FauriatIBiSA Cancer Immunomonitoring Platform, Institut Paoli Calmettes, Inserm, U1068, CRCM, Institut Paoli-Calmettes, CNRS, UMR7258, Aix-Marseille Université, Marseille, France.
Jakub GolabDepartment of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
Daniel OliveIBiSA Cancer Immunomonitoring Platform, Institut Paoli Calmettes, Inserm, U1068, CRCM, Institut Paoli-Calmettes, CNRS, UMR7258, Aix-Marseille Université, Marseille, France.
Radoslaw ZagozdzonDepartment of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
Medical University of Warsaw · PLAix-Marseille Université · FRPostgraduate School of Molecular Medicine · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells are considered critical components of the innate and adaptive immune responses. Deficiencies in NK cell activity are common, such as those that occur in cancer patients, and they can be responsible for dysfunctional immune surveillance. Persistent oxidative stress is intrinsic to many malignant tumours, and numerous studies have focused on the effects of reactive oxygen species on the anti-tumour activity of NK cells. Indeed, investigations in animal models have suggested that one of the most important thiol-dependent antioxidant enzymes, peroxiredoxin 1 (PRDX1), is essential for NK cell function. In this work, our analysis of the transcriptomic expression pattern of antioxidant enzymes in human NK cells has identified PRDX1 as the most prominently induced transcript out of the 18 transcripts evaluated in activated NK cells. The change in PRDX1 expression was followed by increased expression of two other enzymes from the PRDX-related antioxidant chain: thioredoxin and thioredoxin reductase. To study the role of thiol-dependent antioxidants in more detail, we applied a novel compound, adenanthin, to induce an abrupt dysfunction of the PRDX-related antioxidant chain in NK cells. In human primary NK cells, we observed profound alterations in spontaneous and antibody-dependent NK cell cytotoxicity against cancer cells, impaired degranulation, and a decreased expression of activation markers under these conditions. Collectively, our study pinpoints the unique role for the antioxidant activity of the PRDX-related enzymatic chain in human NK cell functions. Further understanding this phenomenon will prospectively lead to fine-tuning of the novel NK-targeted therapeutic approaches to human disease.

Indexed as

Antibody-Dependent Cell CytotoxicityAntioxidantsCell DegranulationCell Line, TumorDiterpenes, KauraneEnzyme InhibitorsGlutathioneHumansKiller Cells, NaturalNeoplasmsOxidative StressPeroxiredoxinsReactive Oxygen SpeciesThioredoxin Reductase 1ThioredoxinsadenanthinAntioxidantsDiterpenes, KauraneEnzyme InhibitorsGlutathionePeroxiredoxinsPRDX1 protein, humanReactive Oxygen SpeciesThioredoxin Reductase 1ThioredoxinsTXN protein, humanTXNRD1 protein, humandegranulationnatural killer cellsoxidative stressperoxiredoxintumour surveillance

Identifiers

PMID26094816
PMCPMC4552512
OpenAlexW1572096297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.